Sagar Lonial, MD, FACP

Articles

Multiple Myeloma: Treatment Options for First Relapse

January 21st 2022

Ola Landgren, MD, PhD; Sagar Lonial, MD; and Joshua Richter, MD, review current available treatment options and factors to consider when selecting therapy for patients with multiple myeloma who experience a first relapse.

Overview of Biochemical vs Clinical Relapse in Myeloma

January 21st 2022

Katja Weisel, MD, and Joshua Richter, MD, define biochemical vs clinical relapses in multiple myeloma and share recommendations for initiating treatment at either stage.

Coming Soon: BCMA-Targeting Agents for Multiple Myeloma

December 23rd 2021

Clinical Case 1: 69-Year-Old Man With Multiple Myeloma (MM)

December 22nd 2021

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Dr. Lonial on Unanswered Questions With T-Cell Engagers in Myeloma

November 23rd 2020

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma

October 6th 2020

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma

August 6th 2020

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Dr. Lonial on the Importance of Early Intervention in High-Risk Smoldering Myeloma

June 3rd 2020

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple Myeloma

May 29th 2020

Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

Dr. Lonial on the Role of Targeted Therapy in AML and ALL

March 28th 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Lonial on Data With Belantamab Mafodotin in Multiple Myeloma

March 11th 2020

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses data with belantamab mafodotin in multiple myeloma.

Dr. Lonial on High-Risk Patients With Smoldering Multiple Myeloma

February 28th 2020

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma

January 10th 2020

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Dr. Lonial on Treatments in Heavily Pretreated Multiple Myeloma

November 16th 2019

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

Dr. Lonial on Treating Early Relapse in Multiple Myeloma

November 12th 2019

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

Dr. Lonial on Advancements in the Treatment of Myeloma

March 2nd 2017

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.